Nature Methods Publication Reveals Single-Molecule Tau Proteoform Insights for Alzheimer's Disease
核心洞察
Nautilus Biotechnology published a peer-reviewed study in Nature Methods demonstrating its Iterative Mapping technology for large-scale, single-molecule analysis of intact tau (搜索) proteoforms.
The Nautilus Tau (搜索) Proteoforms Assay resolved 130 tau proteoform groups from up to 768 biologically feasible groups, quantifying proteoforms present at just 0.1% of a sample with a median coefficient of variation below 5.5%.
Researchers found tau (搜索) modifications accumulate in ordered, non-random sequences, and the most severely affected Alzheimer's patient carried the most heavily phosphorylated tau, including a 1N3R proteoform with four phosphorylation sites.
Nautilus Biotechnology, Inc., a development-stage life sciences company focused on single-molecule proteomics, announced a peer-reviewed publication in Nature Methods demonstrating its Iterative Mapping technology for large-scale analysis of tau (搜索) proteoforms. The study provides a first-of-its-kind single-molecule view of intact tau proteins, identifying disease-associated combinations of modifications that may help reveal new biomarkers and potential drug targets for Alzheimer's disease (搜索) and related tauopathies.
The work addresses a central challenge in neurodegeneration research: understanding which specific forms of tau (搜索) drive disease. "Understanding which forms of tau drive neurodegeneration has been one of the central unanswered questions in our field. Measuring combinatorial modifications on individual, full-length tau molecules at this scale opens a new path to accelerating the search for earlier diagnostics and more precise therapies that patients urgently need," said Joel Blanchard, Ph.D., Associate Professor at The Ronald M. Loeb Center for Alzheimer's Disease (搜索) at Mount Sinai and a collaborator on the study.
Taylor Bertucci, Ph.D., Principal Investigator at the Neural Stem Cell Institute and a collaborator on the study, highlighted the implications for experimental design: "With Iterative Mapping, we now have the unprecedented ability to analyze proteins at the level of distinct proteoforms and to see which variants drive disease. What surprised us most is how differently tau (搜索) behaves across the model systems our field relies on every day. That has immediate consequences for how biomarker studies are designed and how drug programs choose their models."
Resolving Proteoforms at Single-Molecule Resolution
Proteoforms arise from genetic differences, alternative splicing, and post-translational modifications. These subtle differences determine whether a protein supports healthy function or drives disease. Conventional proteomics tools fragment protein molecules or analyze them in bulk, obscuring this functional detail. Iterative Mapping of proteoforms addresses this challenge by measuring fully intact protein molecules with single-molecule resolution at scale, enabling researchers to measure up to billions of individual proteoform molecules in a single run.
The Nautilus Tau (搜索) Proteoforms Assay used in the study employs 12 site-specific antibodies and leverages Iterative Mapping to resolve up to 768 proteoform groups of full-length tau. The assay was run across multiple model systems, including cell-derived and organoid models, mouse brain, and a small cohort of human brain samples spanning cognitively normal individuals and patients with Alzheimer's disease (搜索) and related dementias (ADRD).
Key Findings
The results demonstrate the method's performance and power to potentially surface new biological insights. Of up to 768 resolvable and biologically feasible tau (搜索) proteoform groups, the assay quantified 130 across all samples measured in the study, some carrying as many as six phosphorylation modifications on a single molecule. Conventional methods do not have the resolution to discriminate among these disparate proteoforms. The assay reliably measured proteoforms at 0.1% of a sample, with a median coefficient of variation below 5.5% across a wide range of testing conditions.
Researchers found that specific combinations of tau (搜索) modifications co-occurred far more often than predicted by chance. This suggests that tau is modified in a consistent, ordered sequence rather than through random accumulation, and it underscores the need for methods that can resolve proteoforms to identify novel biomarkers of disease.
Across a small human cohort of five ADRD patients and two cognitively normal individuals, the assay resolved distinct tau (搜索) proteoform profiles. The patient with the most severe pathology carried the most heavily phosphorylated tau, including 1N3R tau quadruply phosphorylated at pT181-pT217-pT231-pS396. Pathology-associated proteoforms like this one have the potential to become powerful biomarkers or drug targets and are uniquely discoverable with Iterative Mapping.
Platform and Pipeline
The Nautilus Voyager Platform employs Nautilus' proprietary Iterative Mapping approach, designed to enable rapid measurement of intact, single-molecule proteins and proteoforms in a single, sample-to-answer workflow. The platform's flow cells are designed to accommodate up to 10 billion intact protein molecules, enabling measurement across an exceptionally wide dynamic range. Iterative Mapping independently probes single protein molecules across tens to hundreds of cycles, recording unique binding patterns for each individual molecule. Machine learning algorithms then convert the resulting probe-binding patterns into confident protein and proteoform identifications.
The Nautilus Tau (搜索) Proteoforms Assay is currently available through the Nautilus Iterative Mapping Early Access Program (EAP). Beyond tau, Nautilus is applying Iterative Mapping to other disease targets, including α-synuclein (搜索) in Parkinson's disease (搜索), and AKT1 (搜索), which is expected to be the company's first oncology proteoform assay. The AKT1 assay is expected to enter the Iterative Mapping EAP in late 2026. Two additional oncology targets have cleared Nautilus' development criteria, highlighting that assay development is anticipated to be a repeatable process. Nautilus is targeting roughly 20 proteoform assays by the middle of 2028.
Nautilus Biotechnology is a development-stage life sciences company with corporate headquarters in Seattle, Washington and research and development headquarters in San Carlos, California. The company's product platform is not yet commercially available and remains subject to scientific and technical development.